Anzeige
+++Pelican AI: +34,75 % in Frankfurt! Ist das erst der Anfang einer großen Kursrallye?+++
Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
Critical Infrastructure Technologies WKN: A3D7R8 ISIN: CA2267401081 Forum: Aktien Thema: Hauptdiskussion
0,10
EUR
±0,00 % ±0,00
15. November 2026, 18:59 Uhr,
Lang & Schwarz
Kostenlose Aktienchance per SMS
Ausgewählte Trading-Einschätzungen aufs Handy.
Kommentare 15.126
d
dernichtswissende,
29.05.2026 18:58 Uhr
2
Ja, das ist richtig. Ich glaube da warten wirklich noch einige drauf. Aber wisst ihr: Wichtig ist, das der Laden halbwegs läuft. Ob der Laden jetzt in 2 Wochen oder in 2 Monaten Früchte trägt, ist mir dann egal. Die Idee ist immernoch gut. Die werden ihren Weg machen, auch wenn die Kommunikation teilweise wirklich dürftig ist.
d
dernichtswissende,
29.05.2026 18:45 Uhr
0
weil die Leute dies interessiert es schon wissen.
A
Animus0202,
29.05.2026 18:41 Uhr
0
Geile Nachrichten
A
Animus0202,
29.05.2026 18:41 Uhr
0
😂😂😂😂😂😂😂🤝
Vorwärtsimmer,
29.05.2026 18:39 Uhr
0
Warum zuckt der Kurs bei der Nachrichtenlage nicht nochmal an?
Coki,
29.05.2026 18:38 Uhr
0
Persönlich warte ich auf finial form 9
Coki,
29.05.2026 18:36 Uhr
0
Form 9 hätt ich noch gern das update 😬🧐
Coki,
29.05.2026 18:06 Uhr
0
Danke Dir Rexona 😘
R
RexonaClassic,
29.05.2026 18:05 Uhr
2
Alles in allem sehr guter Bericht! 🔥🔥🔥 Buy!
d
dernichtswissende,
29.05.2026 17:58 Uhr
0
Denke dann ist alles gesagt. Da wusste einer mehr, und hat gekauft.
d
dernichtswissende,
29.05.2026 17:58 Uhr
0
Noch ein Auszug: As at March 31, 2026, the Company has completed the first design of the SDS and built and delivered the first Nexus
16 to our customers site with all compliance and acceptance testing completed. The Company expects that the building
of the first full-scale pre-production client trial SDSs will allow assembly and production methodologies to be finalised
and cost reduction strategies to be implemented.
Design and functionality improvements continue to occur in relation to the Nexus 16 and work is being done on the
Nexus 20, which provides an additional 4 metres in height.
Marketing efforts have continued with demonstrations of the working ½ scale prototype and the full-scale timber model
which began in December of 2022 with various resource companies. CITP also demonstrated the first completed Nexus
16 in April 2024 at an Industry Demonstration Day, prior to it being delivered to the customer.
As a result of COVID-19, there has been an increase in certain costs together with supply issues on some components,
but not excessively so. Inflation appears to be a problem that the world is currently facing, so we expect there to be
further price increases.
The Company expects that it will continue to be funded by debt and or sales revenue as we now shift to a sales focus,
including the utilization of existing loan facilities available to the Company (such as the loan facility advanced by Radium
Capital), or equity raises until such time as the Company become cash-flow positive. The Company’s subsidiary, CITP,
will also continue to claim the R&D Tax Incentive Rebate.
d
dernichtswissende,
29.05.2026 17:53 Uhr
0
Hier mal ein kleiner Auszug: For the nine months ended March 31, 2026, the Company was focused improving the design of the first full-scale pre-
production platform that was built with continued product marketing across all sectors.
The Company remains in the research and development phase, including advancements to the Nexus 16 and the
development of the Nexus 20 and are currently building 5 Nexus 20.
Sales have commenced this calendar year (2026) and the Company will continue to be funded by debt, including the
utilization of existing loan facilities available to the Company, or equity raises until such time as the Company become
cash-flow positive. The Company, via its wholly owned subsidiary CITP, will also continue to claim the research and
development tax incentive rebate (the “
R&D Rebate
”) that may be available to it or CITP.
Many aspects of the design have now been through rigorous testing, and we have managed to eliminate many of the
design risks. The product is expected to continue to evolve and design changes will be made to ensure seamless
production, whilst maintaining full functionality.
The Company is committed to focusing on the resource, emergency services and defence sectors, as it is the view of
management of the Company that all are in the need for the deployment of rapid mobile telecommunications.
KEY DEVELOPMENTS FOR THE NINE MONTHS ENDED MARCH 31, 2026
A Share Sale Agreement was entered int the acquisition of a steel fabrication business, in Perth, Western Australia,
which is subject to financing.
38,170,661 shares were issued during the period, for a combination of funds received relating to a private placement,
debt settlement, options/warrants exercised and RSU’s vesting. Total cash received for the issue of shares was
$3,989,226.
A
Animus0202,
29.05.2026 17:53 Uhr
0
Ich bin froh vorgestern raus gegangen zu sein
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | Critical Infrastructure Technologies Hauptdiskussion | ||
| 2 | CiTech News Only |
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | Trading- und Aktien-Chat | ||
| 2 | NIKE Hauptdiskussion | ±0,00 % | |
| 3 | Brainchip Klassengruppe | ±0,00 % | |
| 4 | BioNTech Hauptdiskussion | ±0,00 % | |
| 5 | Linien und Wellen Austausch Forum | -3,69 % | |
| 6 | MICRON TECHNOLOGY Hauptdiskussion | -1,26 % | |
| 7 | SMA SOLAR Hauptdiskussion | -0,33 % | |
| 8 | DRONESHIELD LTD Hauptdiskussion | ±0,00 % | |
| 9 | NVIDIA Hauptdiskussion | -1,82 % | |
| 10 | Immunic Hauptdiskussion | ±0,00 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | NIKE Hauptdiskussion | ±0,00 % | |
| 2 | Brainchip Klassengruppe | ±0,00 % | |
| 3 | BioNTech Hauptdiskussion | ±0,00 % | |
| 4 | Linien und Wellen Austausch Forum | -3,69 % | |
| 5 | MICRON TECHNOLOGY Hauptdiskussion | -1,26 % | |
| 6 | SMA SOLAR Hauptdiskussion | -0,33 % | |
| 7 | DRONESHIELD LTD Hauptdiskussion | ±0,00 % | |
| 8 | NVIDIA Hauptdiskussion | -1,82 % | |
| 9 | Immunic Hauptdiskussion | ±0,00 % | |
| 10 | YANDEX Hauptdiskussion | -1,08 % | Alle Diskussionen |